Zacks Small Cap Research on MSN5h
RVPH: Year-End OLE Update
RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...
AI-Powered Drug Development Led to This Recent Breakthrough
Hello, Reader. For all that artificial intelligence has accomplished over the last few years, one thing it has not yet ...
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...
BioSpace1d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Seeking Alpha2d
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...